WeightControl.com Interview with:
Areesha Moiz BSc
Centre of Clinical Epidemiology, Lady Davis Institute
Jewish General Hospital, and Division of Experimental Medicine
McGill University, Montreal, Quebec, Canada
Division of Experimental Medicine
McGill University
WeightControl.com: What is the background for this study?
Response: GLP-1 receptor agonists have been used for type 2 diabetes management for almost two decades. Trials conducted in this patient population also showed some weight loss effects, leading to them being investigated in patients with overweight or obesity and without diabetes. With all the recent buzz around Ozempic (semaglutide) these past few years, we were interested in seeing what other agents in this class of drugs were out there, how they performed for weight loss, and how safe they were.